Response rates to HB vaccine in CKD stages 3-4 and hemodialysis patients

Journal of Research in Medical Sciences

Volumn 17, Issue 6, 2012, Pages 527-533

  Ghadiani, Mohammad H ^a   Besharati, Shahin ^b   Mousavinasab, Nouraddin ^c   Jalalzadeh, Mojgan ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic kidney disease; Hemodialysis; Hepatitis B vaccine; Seroconversion

Indexed keywords

CREATININE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE;

ADULT; AGE; AGED; ANTIBODY TITER; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HEPATITIS B; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL STAFF; PROSPECTIVE STUDY; SEROCONVERSION; STAGING; TREATMENT RESPONSE; VACCINATION;

EID: 84865566056     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Janus N, Vacher LV, Karie S, Ledneva E, Deray G. Vaccination and chronic kidney disease. Nephrol Dial Transplant 2008;23:800-7.
2. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: Epidemiology and vaccination. Epidemiol Rev 2006;28:112-25.
3. CDC. Recommendations of the immunization Practices Advisory Committee (ACIP). Inactivated Hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep 1982;31:317-22.
4. Azarkar Z, Sharifzadeh GH. Efficacy of HBV vaccination in children with thalassemia major, south Khorasan province, Iran. Iranian Red Crescent Medical Journal 2009;11:318-20.
5. Merat S, Rezvan H, Nouraie M, Jamali A, Assari S, Abolghasemi H, et al. The prevalence of Hepatitis B surface antigen and anti-Hepatitis B core antibody in Iran: A population-based study. Arch Iran Med 2009;12:225-31.
6. Poorolajal J, Majdzadeh R. Prevalence of chronic Hepatitis B infection in Iran: A review article. JRes Med Sci 2009;14: 249-58.
7. Tang S, Lai KN. Chronic viral hepatitis in hemodialysis patients. Hemodial Int 2005;9:169-79.
8. Fabrizi F, Martin P. Hepatitis B virus infection in dialysis patients. Am J Nephrol 2000;20:1-11.
9. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005;18:52-61.
10. Igaki N, Nakaji M, Moriguchi R, Akiyama H, Tamada F, Oimomi M, et al. An outbreak of fulminant hepatitis in immunocompromised hemodialysis patients. J Gastroenterol 2003;38:968-76.
11. Tokars JI, Finelli L, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2001. Semin Dial 2004;17:310-9.
12. Fabrizi F, Bunnapradist S, Martin P. HBV infection in patients with end-stage renal disease. Semin Liver Dis 2004;24 (Suppl 1):63-70.
13. Fehr T, Ambühl PM. Chronic hepatitis virus infections in patients on renal replacement therapy. Nephrol Dial Transplant 2004;19:1049-53.
14. Burdick RA, Bragg-Cresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 2002;63:22229.
15. CDC. Recommendations for preventing transmission of infections among chronic haemodialysis patients. MMWR Recomm Rep 2001;50:1-43.
16. Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against Hepatitis B virus in incident chronic hemodialysis patients.Am J Kidney Dis 2000;36:976-82.
17. Tokars JI, Frank M, Alter MJ, Arduino MJ. National surveillance of hemodialysis associated diseases in the United States, 2000. Semin Dial 2002;15:162-71.
18. Liu YL, Kao MT, Huang CC. A comparison of responsiveness to Hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis. Vaccine 2005;23:3957-60.
19. DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, et al. Stage of chronic kidney disease predicts seroconversion after Hepatitis B immunization: Earlier is better. Am J Kidney Dis 2003;42:1184-92.
20. Leehey DJ, Cannon JP, Lentino JR. Handbook of dialysis, John T.Daugirdas, Peter Gerard Blake, Todd S. Ing. 4th ed. 2007. Lippincott Williams & Wilkins, Dec 8, 2006-774 pages.
21. Yoon JW, Gollapudi S, Pahl MV, Vaziri ND. Naive and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int 2006;70:371-6.
22. Pesanti EL. Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin North America 2001;15:813-32.
23. Department of Health. Good practice guidelines for renal dialysis/ transplantation units. Prevention and control of blood-borne virus infection. Recommendation convened by the Public Health Laboratory Service on behalf of the Department of Health. Department of Health Publications; 2002. www.dh.gov.uk
24. Taheri S, Shahidi S, Moghtaderi J, Seirafian S, Emami A, Eftekhari S. Response rate to Hepatitis B vaccination in patients with chronic renal failure and end-stage- renal- disease: Influence of diabetes mellitus. Journal of Research in Medical Sciences, 2005;10:384-90.
25. Dukes CS, Street AC, Starling JF, Hamilton JD. Hepatitis B vaccination and booster in predialysis patients: A 4-year analysis. Vaccine 1993;11:1229-32.
26. Vlassopoulos D. Recombinant Hepatitis B vaccination in renal failure patients. Curr Pharm Biotechnol 2003;4:141-51.
27. Girndt M, Kohler H. Hepatitis B virus infection in haemodialysis patients. Semin Nephrol 2002;22:340-50.
28. Fabrizi F, Ganeshan SV, Dixit V, Martin P. Meta-analysis: The adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to Hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther 2006;24:789-96.
29. Cruciani M, Mengoli C, Serpelloni G, Mazzi R, Bosco O, Malena M. Granulocyte macrophage colony-stimulating factor as an adjuvant for Hepatitis B vaccination: A meta-analysis. Vaccine 2007;25:709-18.
30. Argani H, Akhtarishojaie E. Levamizole enhances immune responsiveness to intra-dermal and intra-muscular Hepatitis B vaccination in chronic hemodialysis patients. J Immune Based Ther Vaccines 2006;4:3.
31. Levin A. Dialysis: Intradermal HBV vaccination is preferable in non-responders. Nat Rev Nephrol 2009;5:616-7.
32. Barraclough KA, Wiggins KJ, Hawley CM, Van Eps CL, Mudge DW, Johnson DW, et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: A prospective openlabel randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis 2009;5 4:95-103. Epub 2009 May 29.
33. Mat O, Mestrez F, Beauwns R, Muniz-Martinez MC, Dhaene M. Primary high dose intradermal Hepatitis B vaccination in hemodialysis: Cost-effectiveness evaluation at 2 years. Hemodial Int 2006;10:49-55.
34. Kong NC, Beran J, Kee SA Miguel JL, Sánchez C, Bayas JM, et al. A new adjuvant improves the immune response to Hepatitis B vaccine in hemodialysis patients. Kidney Int 2008;73:856-62.
35. Morais EO, Resende MR, Oliveira AM, Sinkoc VM, Garcia MT, Angerami RN, et al. Intradermal Hepatitis B vaccination in patients with advanced chronic renal failure: Immunogenicity and followup. Aliment Pharmacol Ther.2007;25:849-55.
36. Fabrizi F, Ganeshan SV, Dixit V, Martin P. Meta-analysis: Intradermal vs. intramuscular vaccination against Hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther 2006;24:497-506.
37. McNulty CA, Bowen JK, Williams AJ. Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules. Vaccine 2005;23:4142-7.
38. Siddiqui S, Malik A, Shukla I, Rizvi M, Haque SF. Seroprotection after Hepatitis B vaccination in chronic kidney disease patients with modified schedule and dosage. J Infect Dev Ctries 2010; 4:389-92.
39. Fraser GM, Ochana N, Fenyves D, Neumann L, Chazan R, Niv Y, et al. Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients. J Hepatol 1994;21:450-4.
40. Watkins SL, Alexander SR, Brewer ED, Hesley TM, West DJ, Chan IS, et al. Response to recombinant Hepatitis B vaccine in children and adolescents with chronic renal failure. AmJKidney 2002;40:365-72.
41. Kara IH, Yilmaz ME, Suner A, Kadiroglu AK, Isikoglu B. The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients. Vaccine 2004;22:3963-7.
42. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Metaanalysis: The effect of age on immunological response to Hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther 2004;20:1053-62.
43. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant Hepatitis B vaccine: A meta-analysis. Clin Infect Dis 2002;35:1368-75.